Indication:
DIFICLIR™ film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.
DIFICLIR™ granules for oral suspension are indicated for the treatment of CDI also known as CDAD in adults and paediatric patients from birth to < 18 years of age.
Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
Formulations: Tablet, granules for oral suspension.
Last update: October 2024.
This medicine is only available upon prescription. The diseases or conditions for the treatment of which this product has been approved by the regulatory authority may not be the same in all countries. This product may not be available in the country where you practice medicine or reside because its supply has not been approved by the local regulatory authority. Healthcare professionals should consult the relevant officially approved prescriber’s information before prescribing or making this product available to patients. Patients and their caregivers should use this product in accordance with the advice of a healthcare professional and the patient information officially approved in their country of residence.